Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma


Clinical Trial Description

Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05371093
Study type Interventional
Source Gilead Sciences
Contact Medical Information
Phone 844-454-5483(1-844-454-KITE)
Email medinfo@kitepharma.com
Status Recruiting
Phase Phase 3
Start date September 12, 2022
Completion date October 2030

See also
  Status Clinical Trial Phase
Recruiting NCT04587388 - Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
Active, not recruiting NCT03939026 - Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma Phase 1
Recruiting NCT05100862 - A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Phase 3
Completed NCT05338879 - Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma
Recruiting NCT04224493 - Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma Phase 3
Recruiting NCT06149286 - A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma Phase 3